Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Hinata Ueda, Katsuya Narumi, Shuho Asano, Yoshitaka Saito, Ayako Furugen & Masaki Kobayashi. (2024) Comparative study on the occurrence of adverse effects in the concomitant use of azathioprine and aldehyde oxidase inhibitors. Expert Opinion on Drug Safety 23:1, pages 89-97.
Read now
Read now
Thomas S. Leyh, Ian Cook & Ting Wang. (2013) Structure, dynamics and selectivity in the sulfotransferase family. Drug Metabolism Reviews 45:4, pages 423-430.
Read now
Read now
Chiaki Tanoue, Kazumi Sugihara, Naoto Uramaru, Yoshitaka Tayama, Yoko Watanabe, Toru Horie, Shigeru Ohta & Shigeyuki Kitamura. (2013) Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes. Xenobiotica 43:11, pages 956-962.
Read now
Read now
James Matthew Hutzler, Ronald Scott Obach, Deepak Dalvie & Michael A Zientek. (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opinion on Drug Metabolism & Toxicology 9:2, pages 153-168.
Read now
Read now
Brian G. Lake & Roger J. Price. (2013) Evaluation of the metabolism and hepatotoxicity of xenobiotics utilizing precision-cut slices. Xenobiotica 43:1, pages 41-53.
Read now
Read now
Enrico Garattini & Mineko Terao. (2012) The role of aldehyde oxidase in drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 8:4, pages 487-503.
Read now
Read now
Inge AM de Graaf, Geny MM Groothuis & Peter Olinga. (2007) Precision-cut tissue slices as a tool to predict metabolism of novel drugs. Expert Opinion on Drug Metabolism & Toxicology 3:6, pages 879-898.
Read now
Read now
Margherita Strolin Benedetti, Rhys Whomsley & Eugène Baltes. (2006) Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opinion on Drug Metabolism & Toxicology 2:6, pages 895-921.
Read now
Read now
Articles from other publishers (45)
Stephani L. Stancil, Robin E. Pearce, Vincent S. Staggs & J. Steven Leeder. (2023) Ontogeny of Scaling Factors for Pediatric Physiologically Based Pharmacokinetic Modeling and Simulation: Cytosolic Protein Per Gram of Liver. Drug Metabolism and Disposition 51:12, pages 1578-1582.
Crossref
Crossref
Kazuko Inoue, Kiyomi Kikuchi, Kazumi Takahashi, Seiji Hitaoka, Kazutomi Kusano & Takafumi Komori. (2023) In Vitro Metabolism of 2-Methoxy-N-[3-[4-[3-methyl-4-[(6-methyl- 3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide (CP-724,714) by Aldehyde Oxidase and Predicting Its Percent Contribution Relative to CYP-Mediated Metabolism. Drug Metabolism and Disposition 51:8, pages 962-969.
Crossref
Crossref
Slobodan P. Rendić, Rachel D. Crouch & F. Peter Guengerich. (2022) Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions. Archives of Toxicology 96:8, pages 2145-2246.
Crossref
Crossref
Dong-Dong Wang, Su-Mei He, Yang Yang, Yi-Zhen Mao, Di Yin, Zi-Qiang Zheng & Xiao Chen. (2022) Effects of cimetidine on ciclosporin population pharmacokinetics and initial dose optimization in aplastic anemia patients. European Journal of Pharmaceutical Sciences 174, pages 106183.
Crossref
Crossref
Somaieh Soltani, Somayeh Hallaj-Nezhadi & Mohammad Reza Rashidi. (2021) A comprehensive review of in silico approaches for the prediction and modulation of aldehyde oxidase-mediated drug metabolism: The current features, challenges and future perspectives. European Journal of Medicinal Chemistry 222, pages 113559.
Crossref
Crossref
Areti-Maria Vasilogianni, Brahim Achour, Daniel Scotcher, Sheila Annie Peters, Zubida M. Al-Majdoub, Jill Barber & Amin Rostami-Hodjegan. (2021) Hepatic Scaling Factors for In Vitro–In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. Drug Metabolism and Disposition 49:7, pages 563-571.
Crossref
Crossref
Omkar Indari, Shweta Jakhmola, Elangovan Manivannan & Hem Chandra Jha. (2021) An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. Frontiers in Pharmacology 12.
Crossref
Crossref
Fikriye Yasemin ÖZATİK. (2021) A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.. Ahi Evran Medical Journal.
Crossref
Crossref
Mailys De Sousa Mendes, Alexandra L. Orton, Helen E. Humphries, Barry Jones, Iain Gardner, Sibylle Neuhoff & Venkatesh Pilla Reddy. (2020) A Laboratory-Specific Scaling Factor to Predict the In Vivo Human Clearance of Aldehyde Oxidase Substrates. Drug Metabolism and Disposition 48:11, pages 1231-1238.
Crossref
Crossref
Wee Kiat Tan, Alyssa Rui Yi Tan, Punitha Sivanandam, Ernest Jing Hui Goh, Ze Ping Yap, Nur Fazilah Saburulla, Karl Austin-Muttitt, Jonathan G.L. Mullins & Aik Jiang Lau. (2020) In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate. Journal of Pharmacology and Experimental Therapeutics 374:2, pages 295-307.
Crossref
Crossref
Yin‐Xiao Du & Xiao‐Ping Chen. (2020) Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection. Clinical Pharmacology & Therapeutics 108:2, pages 242-247.
Crossref
Crossref
Deepak Dalvie & Li Di. (2019) Aldehyde oxidase and its role as a drug metabolizing enzyme. Pharmacology & Therapeutics 201, pages 137-180.
Crossref
Crossref
Shengyun Huang, Getu Kahsay, Erwin Adams & Ann Van Schepdael. (2019) Study of aldehyde oxidase with phthalazine as substrate using both off-line and on-line capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis 165, pages 393-398.
Crossref
Crossref
Jun Hosogi, Rui Ohashi, Hiroshi Maeda, Kazuhiro Fujita, Junko Ushiki, Takashi Kuwabara, Yorihiro Yamamoto & Toru Imamura. (2018) An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW‐2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins. Biopharmaceutics & Drug Disposition 39:3, pages 164-174.
Crossref
Crossref
Alexander V. LyubimovEugene G. Hrycay & Stelvio M. Bandiera. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Erickson M. Paragas, Sara C. Humphreys, Joshua Min, Carolyn A. Joswig-Jones, Silke Leimkühler & Jeffrey P. Jones. (2017) ecoAO: A Simple System for the Study of Human Aldehyde Oxidases Role in Drug Metabolism. ACS Omega 2:8, pages 4820-4827.
Crossref
Crossref
Paula K. Schweitzer & Stephen D. Feren. 2017. Clinical Handbook of Insomnia. Clinical Handbook of Insomnia
97
132
.
R. S. Foti & D. K. Dalvie. (2016) Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. Drug Metabolism and Disposition 44:8, pages 1229-1245.
Crossref
Crossref
C. Zetterberg, F. Maltais, L. Laitinen, S. Liao, H. Tsao, A. Chakilam & N. Hariparsad. (2016) VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions. Drug Metabolism and Disposition 44:8, pages 1286-1295.
Crossref
Crossref
M. A. Cerny. (2016) Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015. Drug Metabolism and Disposition 44:8, pages 1246-1252.
Crossref
Crossref
J. Matthew Hutzler & Michael A. Zientek. 2015. New Horizons in Predictive Drug Metabolism and Pharmacokinetics. New Horizons in Predictive Drug Metabolism and Pharmacokinetics
79
130
.
Maryam Hamzeh‐Mivehroud, Seifullah Rahmani, Mohammad‐Ali Hosseinpour Feizi, Siavoush Dastmalchi & Mohammad‐Reza Rashidi. (2014)
In Vitro
and
In Silico
Studies to Explore Structural Features of Flavonoids for Aldehyde Oxidase Inhibition
. Archiv der Pharmazie 347:10, pages 738-747.
Crossref
Crossref
Kazuko Inoue, Hitoshi Mizuo, Shinki Kawaguchi, Katsuyuki Fukuda, Kazutomi Kusano & Tsutomu Yoshimura. (2014) Oxidative Metabolic Pathway of Lenvatinib Mediated by Aldehyde Oxidase. Drug Metabolism and Disposition 42:8, pages 1326-1333.
Crossref
Crossref
Ian Cook, Ting Wang, Steven C. Almo, Jungwook Kim, Charles N. Falany & Thomas S. Leyh. (2012) The Gate That Governs Sulfotransferase Selectivity. Biochemistry 52:2, pages 415-424.
Crossref
Crossref
Timothy J. Strelevitz, Christine C. Orozco & R. Scott Obach. (2012) Hydralazine As a Selective Probe Inactivator of Aldehyde Oxidase in Human Hepatocytes: Estimation of the Contribution of Aldehyde Oxidase to Metabolic Clearance. Drug Metabolism and Disposition 40:7, pages 1441-1448.
Crossref
Crossref
Alexander V. LyubimovMichael Zientek, Ping Kang, Matthew J. Hutzler & Scott R. Obach. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
59
.
J. Matthew Hutzler, Young-Sun Yang, Daniel Albaugh, Cody L. Fullenwider, Jennifer Schmenk & Michael B. Fisher. (2012) Characterization of Aldehyde Oxidase Enzyme Activity in Cryopreserved Human Hepatocytes. Drug Metabolism and Disposition 40:2, pages 267-275.
Crossref
Crossref
Helen E. Cubitt, J. Brian Houston & Aleksandra Galetin. (2011) Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data. Drug Metabolism and Disposition 39:5, pages 864-873.
Crossref
Crossref
Gabriele M. Böhmer, Christoph H. Gleiter, Klaus Mörike, Nassr Nassr, Antje Walz & Gezim Lahu. (2011) No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine. The Journal of Clinical Pharmacology 51:4, pages 594-602.
Crossref
Crossref
David C. Pryde, Deepak Dalvie, Qiyue Hu, Peter Jones, R. Scott Obach & Thien-Duc Tran. (2010) Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery. Journal of Medicinal Chemistry 53:24, pages 8441-8460.
Crossref
Crossref
Andrew Parkinson, Brian W. Ogilvie, Brandy L. Paris, Tiffini N. Hensley & Greg J. Loewen. 2010. Biotransformation and Metabolite Elucidation of Xenobiotics. Biotransformation and Metabolite Elucidation of Xenobiotics
1
77
.
Deepak Dalvie, Chenghong Zhang, Weichao Chen, Teresa Smolarek, R. Scott Obach & Cho-Ming Loi. (2010) Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences. Drug Metabolism and Disposition 38:4, pages 641-654.
Crossref
Crossref
Sepuri Asha & Maravajhala Vidyavathi. (2009) Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review. Applied Biochemistry and Biotechnology 160:6, pages 1699-1722.
Crossref
Crossref
Nagwa H. Foda & Rana B. Bakhaidar. 2010.
347
371
.
Enrico Garattini, Maddalena Fratelli & Mineko Terao. (2009) The mammalian aldehyde oxidase gene family. Human Genomics 4:2.
Crossref
Crossref
Gary Zammit. (2009) Comparative Tolerability of Newer Agents for Insomnia. Drug Safety 32:9, pages 735-748.
Crossref
Crossref
Manoli Vourvahis & Angela D. M. Kashuba. (2012) Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir‐Enhanced Tipranavir. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:6, pages 888-909.
Crossref
Crossref
Mineko Terao, Mami Kurosaki, Maria Monica Barzago, Emanuela Varasano, Andrea Boldetti, Antonio Bastone, Maddalena Fratelli & Enrico Garattini. (2006) Avian and Canine Aldehyde Oxidases. Journal of Biological Chemistry 281:28, pages 19748-19761.
Crossref
Crossref
Fazlul Huq. (2006) Molecular Modelling Analysis of the Metabolism of Zaleplon. Journal of Pharmacology and Toxicology 1:4, pages 328-336.
Crossref
Crossref
Shigeyuki Kitamura, Kazumi Sugihara & Shigeru Ohta. (2006) Drug-Metabolizing Ability of Molybdenum Hydroxylases. Drug Metabolism and Pharmacokinetics 21:2, pages 83-98.
Crossref
Crossref
Lawrence W. Anderson, Jerry M. Collins, Raymond W. Klecker, Aspandiar G. Katki, Ralph E. Parchment, Ramesh R. Boinpally, Patricia M. LoRusso & S. Percy Ivy. (2005) Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug–drug interactions. Cancer Chemotherapy and Pharmacology 56:4, pages 351-357.
Crossref
Crossref
Tobias Engl, Kim A. Boost, Kerstin Leckel, Wolf-Dietrich Beecken, Dietger Jonas, Elsie Oppermann, Marcus K.H. Auth, André Schaudt, Wolf-Otto Bechstein & Roman A. Blaheta. (2004) Phosphorylation of hepatocyte growth factor receptor and epidermal growth factor receptor of human hepatocytes can be maintained in a (3D) collagen sandwich culture system. Toxicology in Vitro 18:4, pages 527-532.
Crossref
Crossref
R. Scott Obach, Phuong Huynh, Mary C. Allen & Christine Beedham. (2013) Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs. The Journal of Clinical Pharmacology 44:1, pages 7-19.
Crossref
Crossref
R. Scott Obach. (2004) POTENT INHIBITION OF HUMAN LIVER ALDEHYDE OXIDASE BY RALOXIFENE. Drug Metabolism and Disposition 32:1, pages 89-97.
Crossref
Crossref
Christine Beedham, Jeffrey J. Miceli & R. Scott Obach. (2003) Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications. Journal of Clinical Psychopharmacology 23:3, pages 229-232.
Crossref
Crossref